What is GLPGF stock price today?

GLPGF (Galapagos Nv) stock is trading at $33.27 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is GLPGF stock going up or down today?

GLPGF stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy GLPGF stock now?

The decision to buy GLPGF depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is GLPGF a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for GLPGF based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is GLPGF stock overvalued or undervalued?

Use our DCF valuation calculator to determine if GLPGF is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is GLPGF's P/E ratio?

P/E ratio data for GLPGF will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is GLPGF's market cap?

GLPGF (Galapagos Nv) has a market capitalization of $3.21 billion, making it a small-cap stock.

What is GLPGF's price to book ratio?

GLPGF trades at a price-to-book (P/B) ratio of 0.76, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does GLPGF pay dividends?

GLPGF does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is GLPGF's dividend yield?

GLPGF does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is GLPGF stock a good long-term investment?

GLPGF's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is GLPGF's revenue growth rate?

GLPGF has shown revenue growth of 10.9% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, GLPGF is profitable with a profit margin of 0.3%. This indicates the company generates 0.3 cents of profit for every dollar of revenue.

What are the risks of investing in GLPGF?

Key risks for GLPGF include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does GLPGF compare to its competitors?

Compare GLPGF to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize GLPGF's performance and positioning.

What is GLPGF's stock price target for 2026?

Our AI model provides price targets for GLPGF based on fundamental analysis: Bull case $43.25 (+30%), Base case $38.26 (+15%), Bear case $29.94 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about GLPGF?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for GLPGF. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is GLPGF's next earnings report?

GLPGF reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

GLPGF - Galapagos Nv

NYSE * Healthcare * Biotechnology

$33.27

+$0.00 (+0.00%)

About Galapagos Nv

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

GLPGF Key Statistics

Market Cap

$3.21B

P/B Ratio

0.76

EPS

$-7.92

Revenue Growth

+10.9%

Profit Margin

0.3%

Employees

704

How GLPGF Compares to Peers

GLPGF has the fastest revenue growth among competitors

GLPGF is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
GLPGF(This stock)	$3.21B	N/A	11%	0.3%	-
AMGNAmgen Inc	$199.20B	25.8	0%	0.2%	vs AMGN
GILDGilead Sciences	$178.68B	21.4	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$116.00B	30.1	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$80.33B	18.5	0%	0.3%	vs REGN
BIIBBiogen Inc	$27.13B	21.4	-0%	0.1%	vs BIIB

Galapagos Nv Company Information

Headquarters: Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800, undefined
Website: www.glpg.com
Sector: Healthcare
Industry: Biotechnology

About Galapagos Nv

GLPGF Key Statistics

How GLPGF Compares to Peers

Galapagos Nv Company Information

Upcoming Events for GLPGF